|
Non-invasive ventilation and dexmedetomidine in critically ill adults: a vanguard pragmatic randomized controlled trial (inDEX trial)
|
Ongoing
|
dexmedetomidine , Non-invasive ventilation
|
3
|
SCT22R/001/01
|
King Abdulaziz Medical City NG (Riyadh)
|
|
A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With Nusinersen
|
Ongoing
|
Nusinersen (Spinraza)
|
3
|
232SM302
|
King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Specialist Hospital (Dammam),King Abdulaziz Medical City NG (Jeddah)
|
|
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease
|
Ongoing
|
FT-4202
|
2/3
|
4202-HEM-301
|
King Khalid University Hospital (Riyadh),Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabia
|
|
EPIK-B4: A Phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy
|
Completed
|
BYL719 / Alpelisib
|
2
|
CBYL719C2202
|
King Fahad Specialist Hospital (Dammam),King Khalid University Hospital (Riyadh)
|
|
Multinational Survey-Based Chart Review Study in International Markets to Evaluate the Effectiveness, Safety, and Treatment Patterns of DUPIXENT® (Dupilumab) in Patients with Moderate-to-Severe Atopic Dermatitis
|
Completed
|
DUPIXENT® (Dupilumab)
|
4
|
DUT0012
|
Specialized Medical Center (Riyadh),Dr. Erfan & Bagedo General Hospital (Jeddah)
|
|
A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non–Transfusion-Dependent Alpha or Beta Thalassemia (ENERGIZE)
|
Ongoing
|
Mitapivat
|
3
|
AG348-C-017
|
King Khalid University Hospital (Riyadh),King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Hospital NG (Al Ahsa)
|
|
A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha or Beta Thalassemia (ENERGIZE-T)
|
Ongoing
|
Mitapivat
|
3
|
AG348-C-018
|
King Khalid University Hospital (Riyadh),King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Hospital NG (Al Ahsa)
|
|
A Multi-Country Observational Retrospective Study to Evaluate the Prevalence of PD-L1 and its Role in Patients with TNBC Treated with Systemic Therapy (VANESSA)
|
Ongoing
|
N/A
|
4
|
MO42921
|
King Faisal Specialist Hospital and Research Center (Riyadh),King Abdulaziz Medical City NG (Riyadh)
|
|
A multi-centre, prospective, non-interventional single-arm study investigating clinical parameters associated with the use of once-daily oral semaglutide in a real-world adult
|
Ongoing
|
Oral semaglutide (Rybelsus®)
|
4
|
NN9924-4542
|
Specialized Medical Center (Riyadh),My Clinic (Jeddah),Dallah Hospital (Riyadh),Dr. Sulaiman Al-Habib Medical Group (Riyadh),Dr. Soliman Fakeeh Hospital (Jeddah),Saudi German Hospital (Jeddah),Almoosa Hospital,Mouwasat Hospital
|
|
A Retrospective Chart Review Combined with a Prospective Cross-sectional Survey and Interviews on Patients with Type 2 Diabetes Mellitus to Assess Effectiveness of Adding SodiumGlucose Co-transporter 2 Inhibitor to Gliclazide Modified Release
|
Ongoing
|
SodiumGlucose Co-transporter 2 Inhibitor added to Gliclazide Modified Release
|
4
|
DIM-05762
|
King Khalid University Hospital (Riyadh),King Abdulaziz University Hospital (Jeddah),Ghassan Najeeb Pharaon hospital (Jeddah)
|
